|1.||Shayman, James A: 4 articles (12/2015 - 01/2010)|
|2.||Addington, W Robert: 4 articles (01/2008 - 05/2003)|
|3.||Widdicombe, John G: 4 articles (01/2008 - 05/2003)|
|4.||Stephens, Robert E: 4 articles (01/2008 - 05/2003)|
|5.||Rabasseda, X: 4 articles (12/2006 - 07/2004)|
|6.||Prous, J R: 4 articles (12/2006 - 07/2004)|
|7.||Hanania, Nicola A: 3 articles (12/2014 - 02/2007)|
|8.||Peterschmitt, M Judith: 3 articles (05/2011 - 08/2010)|
|9.||Puga, Ana Cristina: 3 articles (05/2011 - 08/2010)|
|10.||Bayes, M: 3 articles (12/2006 - 07/2004)|
|1.||Gaucher Disease (Gaucher's Disease)
11/18/2010 - "Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study."
01/01/2013 - "Eliglustat tartrate was the result of these efforts and is currently the focus of phase 3 trials for type 1 Gaucher disease. "
12/01/2010 - "eliglustat tartrate for Gaucher disease) are currently under investigation in various clinical trials."
10/01/2010 - "In a phase Ib clinical trial in healthy volunteers, plasma glucocerebroside concentrations were decreased after dosing with eliglustat tartrate, and in phase II clinical trials in patients with type 1 (non-neuronopathic) Gaucher disease, spleen and liver volumes were diminished. "
08/12/2010 - "A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1."
07/01/1990 - "Controlled clinical trials demonstrated protireline tartrate (TRH-T) efficacy, with its analeptic, analgesic and arousing effects, in the treatment of neurological and functional impairment due to cerebrovascular accidents and head injuries. "
07/01/1990 - "The effects of protirelin tartrate (TRH-T) administration on chronic post-stroke spasticity were studied in a multicentre trial (study on the treatment of chronic post-stroke spasticity--11 centres involved). "
07/01/1990 - "[Neuropsychologic and clinical effects of protirelin tartrate in patients with stroke sequelae]."
07/01/1990 - "[The role of protirelin tartrate (TRH-T) in the rehabilitation of the post-stroke patient. "
07/01/1990 - "[Role of protirelin tartrate (TRH-T) in the recovery of post-stroke patients]."
07/01/2013 - "Experiments with aluminium acetate-tartrate preparations on animals and clinical trials are required to obtain information about the response rates in ear infections and about any adverse effects."
10/01/2012 - "In this study, the population structure, incidence, and potential sources of human infection caused by the d-tartrate-fermenting variant of Salmonella enterica serovar Paratyphi B [S. "
10/01/2012 - "Human infections attributable to the D-tartrate-fermenting variant of Salmonella enterica serovar Paratyphi B in Germany originate in reptiles and, on rare occasions, poultry."
02/03/2012 - "CDC is collaborating with the Pennsylvania State Health Department in an ongoing investigation of an outbreak of human Salmonella enterica serotype Paratyphi B var. L (+) tartrate + infections associated with pet turtle exposures. "
01/25/2008 - "In October 2007, the North Carolina Division of Public Health (NCDPH) notified CDC of human infections caused by Salmonella serotype Paratyphi B L (+) tartrate (+) (Salmonella Paratyphi B var. Java) in several states. "
12/01/1999 - "Evaluation of the endosteal bone surface features showed significantly greater bone resorption in the Mg depleted group as reflected in increased number of tartrate-resistant positive osteoclasts/mm bone surface (7.8 vs 4.0 in controls) and an elevated percent of bone surface occupied by osteoclasts (percent OcS/BS = 12.2 percent vs 6.7 percent in controls. "
01/01/2012 - "This study sought to test whether targeted overexpression of osteoactivin (OA) in cells of osteoclastic lineage, using the tartrate-resistant acid phosphase (TRAP) exon 1B/C promoter to drive OA expression, would increase bone resorption and bone loss in vivo. "
08/01/2011 - "Quantification of RANKL immunofluorescence, fluorescence-based tartrate-resistant acid phosphatase+ (TRAP+) osteoclast counts and histological analyses of the bone resorption area were performed and clinically correlated after a 32-day in vivo experiment comparing corticotomy and gene therapy. "
04/01/2008 - "[Tartrate resistant acid phosphatase--TRACP-5b as a modern bone resorption marker]."
09/01/1998 - "In both the teeth filled with the dentin powder and those filled with TBC, multinucleate giant cells appeared on the bone resorption surface and the surface of the root canal wall, and marked bone resorption and positive tartrate-resistant acid phosphate staining were observed. "
07/01/2006 - "Oxalic acid and tartaric acid were identified, for the first time, as major long-lasting pain-inducing toxins in the stinging hairs of U. "
07/01/2006 - "The behavioural tests showed that 2% oxalic acid and 10% tartaric acid dramatically elicited persistent pain sensations in rats. "
07/01/2006 - "Identification of oxalic acid and tartaric acid as major persistent pain-inducing toxins in the stinging hairs of the nettle, Urtica thunbergiana."
06/01/2009 - "The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats."
01/01/1988 - "The results indicated that naproxen sodium gave statistically significantly greater pain relief than dihydrocodeine tartrate after the first dose. "
|5.||Thyrotropin-Releasing Hormone (Protirelin)
|9.||Bupivacaine (Bupivacaine Hydrochloride)
|4.||Dry Powder Inhalers